LEADER 01130nam--2200349---450- 001 990003636820203316 005 20120309140135.0 010 $a978-88-6342-270-2 035 $a000363682 035 $aUSA01000363682 035 $a(ALEPH)000363682USA01 035 $a000363682 100 $a20120309d2011----km-y0itay50------ba 101 $aita 102 $aIT 105 $ay|||||||001yy 200 1 $aPerequazione e compensazione nel governo del territorio della Toscana$fa cura di Gian Franco Cartei e Enrico Amante 210 $aNapoli$cEditoriale scientifica$d2011 215 $aX, 165 p.$d24 cm 606 0 $aPianificazione territoriale$yToscana$2BNCF 676 $a711.309455$v22 701 21$aCARTEI,$bGian Franco$0148865 702 1$aAMANTE,$bEnrico 801 0$aIT$bsalbc$gISBD 912 $a990003636820203316 951 $a711.309 PER 1$b73250 G.$c711.309$d00308148 959 $aBK 969 $aECO 979 $aCHIARA$b90$c20120309$lUSA01$h1400 979 $aCHIARA$b90$c20120309$lUSA01$h1401 996 $aPerequazione e compensazione nel governo del territorio della Toscana$91137803 997 $aUNISA LEADER 03271nam 2200661Ia 450 001 9910781450603321 005 20230725053809.0 010 $a0-19-174025-X 010 $a0-19-960737-0 010 $a1-283-34833-0 010 $a9786613348333 010 $a0-19-157581-X 035 $a(CKB)2550000000064626 035 $a(EBL)797725 035 $a(OCoLC)763157034 035 $a(SSID)ssj0000555589 035 $a(PQKBManifestationID)12244098 035 $a(PQKBTitleCode)TC0000555589 035 $a(PQKBWorkID)10519626 035 $a(PQKB)10355720 035 $a(MiAaPQ)EBC797725 035 $a(StDuBDS)EDZ0000091506 035 $a(Au-PeEL)EBL797725 035 $a(CaPaEBR)ebr10511371 035 $a(CaONFJC)MIL334833 035 $a(MiAaPQ)EBC7039287 035 $a(Au-PeEL)EBL7039287 035 $a(EXLCZ)992550000000064626 100 $a20100924d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aSystemic treatment of prostate cancer$b[electronic resource] /$fedited by Alan Horwich 210 $aOxford ;$aNew York $cOxford University Press$d2010 215 $a1 online resource (102 p.) 225 1 $aOxford oncology library 300 $aDescription based upon print version of record. 311 $a0-19-956142-7 320 $aIncludes bibliographical references and index. 327 $aContents; Preface; Symbols and abbreviations; Contributors; 1 Biological principles of hormone therapy; 2 PSA as a marker of progression and response in advanced prostate cancer; 3 Neo-adjuvant and adjuvant hormone therapy for high-risk localized prostate cancer; 4 Systemic treatment of recurrence after local therapies; 5 First-line hormone therapy for metastatic prostate cancer; 6 Second- and third-line hormone therapies; 7 Chemotherapy for metastatic prostate cancer; 8 The role of bisphosphonates in the systemic treatment of prostate cancer; 9 Systemic isotope therapy of bone metastasis 327 $a10 Biological targets and new drug development for prostate cancerIndex; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; R; S; T; U; V; W; Z 330 $aProstate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay ofendocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroids can also cause r 410 0$aOxford oncology library. 606 $aProstate$xCancer$xDiagnosis 606 $aProstate$xCancer$xTreatment 615 0$aProstate$xCancer$xDiagnosis. 615 0$aProstate$xCancer$xTreatment. 676 $a616.9946306 701 $aHorwich$b Alan$01493544 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910781450603321 996 $aSystemic treatment of prostate cancer$93716555 997 $aUNINA